leisure time -WSS

leisure time

author：knowledge 2025-09-30 18:00:48 - browse：24

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Commercial surrogacy can be ethical, despite pope’s claims

leisure time

WSS

Biden administration opens offers in Medicare drug price negotiations

Do digital therapeutics have a future in medicine?

HHS's proposed rule does nothing to address the climate crisis

Woodcock on FDA’s accelerated approval and her next chapter

Do digital therapeutics have a future in medicine?

Warren pushes Witty on UnitedHealth's control over physicians

explore

leisure time

focus

Activists slam private health insurers over coverage restrictions

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Activists slam private health insurers over coverage restrictions

BIO to announce reorganization, senior leaders expected to depart

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A $475,000 price tag for a new cancer drug: crazy or meh?

Sports medicine is finally prioritizing gender equality

ARCH Venture Partners is raising $3 billion for a life sciences fund

BioMarin wins approval for gene therapy to treat hemophilia A

The real point of Kenneth Smith’s execution by nitrogen gas

focus

ARCH Venture Partners is raising $3 billion for a life sciences fund

Is it ever OK for doctors to lie to their patients?

Chemotherapy before breast cancer surgery might fuel metastasis

Covid misinformation case heads to Supreme Court

Vertigo drug brings hope for rare neuron disorder, Niemann

Welsh Carson private equity firm escapes from FTC antitrust case

Wikipedia

leisure time

entertainment

leisure time